Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18121547 | 0.90 | KMT2A (0.57) | CA12CA1CA2CA7XDH | |
| SCHEMBL3005074 | 0.85 | CA12 (0.56) | CA12CA1CA2CA7XDH | |
| SCHEMBL18329185 | 0.82 | CA1 (0.62) | CA12CA1CA2CA7XDH | |
| SCHEMBL13851150 | 0.81 | NSD2 (0.76) | CA12CA1CA2CA7XDH | |
| SCHEMBL18121555 | 0.81 | CA1 (0.61) | CA12CA1CA2CA7XDH | |
| SCHEMBL15948378 | 0.81 | CA1 (0.61) | CA12CA1CA2CA7XDH | |
| SCHEMBL3006067 | 0.81 | NSD2 (0.73) | CA12CA1CA2CA7XDH | |
| SCHEMBL13286874 | 0.81 | CA12 (0.62) | CA12CA1CA2CA7XDH | |
| SCHEMBL18121548 | 0.80 | LMNA (0.54) | CA12CA1CA2CA7XDH | |
| SCHEMBL2994752 | 0.80 | NSD2 (0.47) | CA12CA1CA2CA7XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | claimed |
| EP-2170802-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) | 2010-04-07 | — | — | EP | claimed |
| WO-2009000864-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA (ES) | 2008-12-31 | — | — | WO | claimed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2010-07-29 | — | — | US | disclosed |
| EP-2170802-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009000864-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA (ES) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000864-A1 | NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA (ES) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190856-A1 | Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors | FASN, SCD, FADS2 | CA12 4827/4885CA1 4396/4885CA2 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.